Background: The rate of adverse clinical outcomes among patients with asymptomatic carotid stenosis receiving medical therapy alone can be used to guide clinical decision-making and to inform future research. We aimed to investigate temporal changes in the incidence rate of clinical outcomes among patients with asymptomatic carotid stenosis receiving medical therapy alone and to explore the implications of these changes for the design of future comparative studies. Summary: We searched MEDLINE, the Cochrane Central Register of Controlled Trials, US Food and Drug Administration documents, and reference lists of included studies (last search: December 31, 2012). We selected prospective cohort studies of medical therapy for asymptomatic carotid artery stenosis and we extracted information on study characteristics, risk of bias, and outcomes. We performed meta-analyses to estimate summary incidence rates, meta-regressions to assess trends over time, and simulations to explore sample size requirements for the design of future studies comparing new treatments against medical therapy. The main outcomes of interest were ipsilateral stroke, any stroke, cardiovascular death, death, and myocardial infarction. We identified 41 studies of medical therapy for patients with asymptomatic carotid stenosis (last recruitment year: 1978-2009). The summary incidence rate of ipsilateral carotid territory stroke (25 studies) was 1.7 per 100 person-years. This incidence rate was significantly lower in recent studies (last recruitment year from 2000 onwards) as compared to studies that ended recruitment earlier (1.0 vs. 2.3 events per 100 person-years; p < 0.001). The incidence rates of any territory stroke (17 studies), cardiovascular death (6 studies), death (13 studies), and myocardial infarction (5 studies) were 2.7, 4.1, 4.6, and 1.8 per 100 person-years, respectively. Simulations showed that future studies would need to enroll large numbers of patients with a relatively high incidence rate under medical therapy, and evaluate interventions with large effect sizes, to have adequate power to reliably detect treatment effects. Key Messages: Improved prognosis under medical therapy alone has narrowed the potential range of risk reduction attainable with new treatments for asymptomatic carotid stenosis. Future comparative studies will need to enroll large numbers of patients to assess treatment effectiveness.

Keywords:
Asymptomatic carotid stenosis, Medical therapy, Meta-analysis, Meta-regression
1.
Rijbroek A, Wisselink W, Vriens EM, Barkhof F, Lammertsma AA, Rauwerda JA: Asymptomatic carotid artery stenosis: past, present and future. How to improve patient selection? Eur Neurol 2006;56:139-154.
2.
Raman G, Moorthy D, Hadar N, Dahabreh IJ, O'Donnell TF, Thaler DE, Feldmann E, Lau J, Kitsios GD: Management strategies for asymptomatic carotid stenosis: a systematic review and meta-analysis. Ann Intern Med 2013;158:676-685.
3.
Brott TG, Halperin JL, Abbara S, Bacharach JM, Barr JD, Bush RL, Cates CU, Creager MA, Fowler SB, Friday G, Hertzberg VS, McIff EB, Moore WS, Panagos PD, Riles TS, Rosenwasser RH, Taylor AJ: 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease: executive summary. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American Stroke Association, American Association of Neuroscience Nurses, American Association of Neurological Surgeons, American College of Radiology, American Society of Neuroradiology, Congress of Neurological Surgeons, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Neurointerventional Surgery, Society for Vascular Medicine, and Society for Vascular Surgery. Circulation 2011;124:489-532.
4.
Brott TG, Halperin JL, Abbara S, Bacharach JM, Barr JD, Bush RL, Cates CU, Creager MA, Fowler SB, Friday G, Hertzberg VS, McIff EB, Moore WS, Panagos PD, Riles TS, Rosenwasser RH, Taylor AJ: 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American Stroke Association, American Association of Neuroscience Nurses, American Association of Neurological Surgeons, American College of Radiology, American Society of Neuroradiology, Congress of Neurological Surgeons, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Neurointerventional Surgery, Society for Vascular Medicine, and Society for Vascular Surgery. Circulation 2011;124:e54-e130.
5.
Goldstein LB, Bushnell CD, Adams RJ, Appel LJ, Braun LT, Chaturvedi S, Creager MA, Culebras A, Eckel RH, Hart RG, Hinchey JA, Howard VJ, Jauch EC, Levine SR, Meschia JF, Moore WS, Nixon JV, Pearson TA: Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011;42:517-584.
6.
Alsheikh-Ali AA, Kitsios GD, Balk EM, Lau J, Ip S: The vulnerable atherosclerotic plaque: scope of the literature. Ann Intern Med 2010;153:387-395.
7.
Silver B, Zaman IF, Ashraf K, Majed Y, Norwood EM, Schuh LA, Smith BJ, Smith RE, Schultz LR: A randomized trial of decision-making in asymptomatic carotid stenosis. Neurology 2012;78:315-321.
8.
Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. JAMA 1995;273:1421-1428.
9.
Abbott AL: Medical (nonsurgical) intervention alone is now best for prevention of stroke associated with asymptomatic severe carotid stenosis: results of a systematic review and analysis. Stroke 2009;40:e573-e583.
10.
Spence JD: Asymptomatic carotid stenosis. Circulation 2013;127:739-742.
11.
White CJ, Jaff MR: Catch-22: carotid stenting is safe and effective (Food and Drug Administration) but is it reasonable and necessary (Centers for Medicare and Medicaid Services)? JACC Cardiovasc Interv 2012;5:694-696.
12.
Abbott AL, Adelman MA, Alexandrov AV, et al: Why calls for more routine carotid stenting are currently inappropriate: an international, multispecialty, expert review and position statement. Stroke 2013;44:1186-1190.
13.
Kent DM, Trikalinos TA: Therapeutic innovations, diminishing returns, and control rate preservation. JAMA 2009;302:2254-2256.
14.
Scannell JW, Blanckley A, Boldon H, Warrington B: Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov 2012;11:191-200.
15.
Raman G, Kitsios GD, Moorthy D, Hadar N, Dahabreh IJ, O'Donnell TF, Thaler DE, Feldmann E, Lau J: Management of asymptomatic carotid stenosis. Bethesda, Agency for Healthcare Research and Quality, 2012.
16.
Paulus JK, Dahabreh IJ, Balk EM, Avendano EE, Lau J, Ip S: Opportunities and challenges in using studies without a control group in comparative effectiveness reviews. Res Synth Methods 2014;5:152-161.
17.
Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB: Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-Analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008-2012.
18.
Wadden TA, Webb VL, Moran CH, Bailer BA: Lifestyle modification for obesity: new developments in diet, physical activity, and behavior therapy. Circulation 2012;125:1157-1170.
19.
Parmar MK, Torri V, Stewart L: Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998;17:2815-2834.
20.
Shadish WR, Brasil IC, Illingworth DA, White KD, Galindo R, Nagler ED, Rindskopf DM: Using UnGraph to extract data from image files: verification of reliability and validity. Behav Res Methods 2009;41:177-183.
21.
Ip S, Paulus JK, Balk EM, Dahabreh IJ, Avendano EE, Lau J: Role of single group studies in Agency for Healthcare Research and Quality comparative effectiveness reviews, ed 2013/02/22. Report No 13-EHC007-EF. Rockville, Agency for Healthcare Research and Quality, 2013.
22.
Kitsios GD, Dahabreh IJ, Abu Dabrh AM, Thaler DE, Kent DM: Patent foramen ovale closure and medical treatments for secondary stroke prevention: a systematic review of observational and randomized evidence. Stroke 2012;43:422-431.
23.
Greenland S: Invited commentary: a critical look at some popular meta-analytic methods. Am J Epidemiol 1994;140:290-296.
24.
Greenland S, O'Rourke K: On the bias produced by quality scores in meta-analysis, and a hierarchical view of proposed solutions. Biostatistics 2001;2:463-471.
25.
Hamza TH, van Houwelingen HC, Stijnen T: The binomial distribution of meta-analysis was preferred to model within-study variability. J Clin Epidemiol 2008;61:41-51.
26.
Stijnen T, Hamza TH, Ozdemir P: Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data. Stat Med 2010;29:3046-3067.
27.
Rothman KJ: No adjustments are needed for multiple comparisons. Epidemiology 1990;1:43-46.
28.
Fisher RA: The logic of inductive inference. J R Stat Soc 1935;98:39-82.
29.
Feiveson A: Power by simulation. Stata J 2002;2:107-124.
30.
Naylor AR: What is the current status of invasive treatment of extracranial carotid artery disease? Stroke 2011;42:2080-2085.
31.
Toole JF, Castaldo JE: Accurate measurement of carotid stenosis. Chaos in methodology. J Neuroimaging 1994;4:222-230.
32.
Hong KS, Yegiaian S, Lee M, Lee J, Saver JL: Declining stroke and vascular event recurrence rates in secondary prevention trials over the past 50 years and consequences for current trial design. Circulation 2011;123:2111-2119.
33.
Yusuf S, Collins R, Peto R: Why do we need some large, simple randomized trials? Stat Med 1984;3:409-422.
34.
Bogiatzi C, Cocker MS, Beanlands R, Spence JD: Identifying high-risk asymptomatic carotid stenosis. Expert Opin Med Diagn 2012;6:139-151.
35.
Kakkos SK, Griffin MB, Nicolaides AN, Kyriacou E, Sabetai MM, Tegos T, Makris GC, Thomas DJ, Geroulakos G: The size of juxtaluminal hypoechoic area in ultrasound images of asymptomatic carotid plaques predicts the occurrence of stroke. J Vasc Surg 2013;57:609-618.e1, discussion 617-618.
36.
Momjian-Mayor I, Kuzmanovic I, Momjian S, Bonvin C, Albanese S, Bichsel D, Comelli M, Pereira VM, Lovblad KO, Sztajzel RF: Accuracy of a novel risk index combining degree of stenosis of the carotid artery and plaque surface echogenicity. Stroke 2012;43:1260-1265.
37.
Topakian R, King A, Kwon SU, Schaafsma A, Shipley M, Markus HS: Ultrasonic plaque echolucency and emboli signals predict stroke in asymptomatic carotid stenosis. Neurology 2011;77:751-758.
38.
Madani A, Beletsky V, Tamayo A, Munoz C, Spence JD: High-risk asymptomatic carotid stenosis: ulceration on 3D ultrasound vs TCD microemboli. Neurology 2011;77:744-750.
39.
Feinstein AR, Sosin DM, Wells CK: The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 1985;312:1604-1608.
40.
Sytkowski PA, Kannel WB, D'Agostino RB: Changes in risk factors and the decline in mortality from cardiovascular disease. The Framingham Heart Study. N Engl J Med 1990;322:1635-1641.
41.
Rothwell PM, Coull AJ, Giles MF, Howard SC, Silver LE, Bull LM, Gutnikov SA, Edwards P, Mant D, Sackley CM, Farmer A, Sandercock PA, Dennis MS, Warlow CP, Bamford JM, Anslow P: Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). Lancet 2004;363:1925-1933.
42.
Tolonen H, Mahonen M, Asplund K, Rastenyte D, Kuulasmaa K, Vanuzzo D, Tuomilehto J: Do trends in population levels of blood pressure and other cardiovascular risk factors explain trends in stroke event rates? Comparisons of 15 populations in 9 countries within the WHO MONICA Stroke Project. World Health Organization Monitoring of Trends and Determinants in Cardiovascular Disease. Stroke 2002;33:2367-2375.
43.
Harmsen P, Wilhelmsen L, Jacobsson A: Stroke incidence and mortality rates 1987-2006 related to secular trends of cardiovascular risk factors in Gothenburg, Sweden. Stroke 2009;40:2691-2697.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.